Mohamed Y. Zakaria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohamed Y. Zakaria has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Ali Al-Karmalawy
Department of Pharmaceutical Chemistry, College of Pharmacy The University of Mashreq Baghdad Iraq
2 shared publications Maha M. Amin
2 shared publications- Maha Mohamed Amin
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
2 shared publications - Marium M. Shamaa
Biochemistry Department, Clinical and Biological Sciences Division, College of Pharmacy, Arab Academy for Science Technology and Maritime Transport, Alexandria 1029, Egypt
2 shared publications Radwan Alnajjar
Department of Chemistry, Faculty of Science, University of Benghazi, Benghazi, Libya; PharmD, Faculty of Pharmacy, Libyan International Medical University, Benghazi, Libya; Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
2 shared publications- Rana E. Elnady
Department of Pharmaceutics, Faculty of Pharmacy, Sinai University–Arish Branch, Arish 45511, Egypt
2 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (4)
PEGylated Flavonoid Aspasomes as a Brain-Targeted Nano-Vesicular Platform for Enhanced Neuroprotection in Stress-Induced Cognitive Dysfunction
Luteolin (LUT) is a biologically active flavonoid exhibiting significant therapeutic potential against neurodegenerative disorders such as cognitive impairment. Nonetheless, its clinical application is limited by poor aqueous solubility, extensive first-pass metabolism and diminished permeability across the blood-brain barrier (BBB) and consequently, low oral bioavailability. This study aimed to develop PEGylated LUT nano-vesicular delivery systems to enhance brain delivery and therapeutic efficacy. PEGylated LUT-Aspasomes were prepared via thin-film hydration, using Brij 52 for PEGylation. Sixteen formulations were designed using a 24 full factorial design, varying the weights of Ascorbyl Palmitate (AP), Cholesterol (CH), Brij 52, and Span (Sp) type. The optimized formulation (F14) is composed of 40 mg AP and CH, 10 mg Brij 52, and 50 mg Sp 60 with a desirability value (0.747). F14 demonstrated entrapment efficiency (EE%) (86.24 ± 1.16%), particle size (PS) (188.30 ± 1.50 nm), and zeta potential (ZP) (-25.31 ± 0.84 mV). TEM confirmed spherical, nanosized vesicles with uniform morphology. XRD analysis revealed transformation of LUT from crystalline to amorphous form, supporting successful encapsulation. Drug release and ex-vivo nasal permeation were enhanced 3.4- and fourfold, respectively, compared to free LUT. In-vivo studies in chronic unpredictable stress (CUS) rats revealed that the optimized PEGylated LUT-Aspasomes significantly enhanced neuroprotective effects compared to free LUT. Treated rats exhibited improved spatial memory and a 1.7-fold greater attenuation of depressive-like behavior relative to free LUT. Biochemically, F14 produced 1.15-, 1.23-, and 1.06-fold superior reductions in hippocampal acetylcholinesterase (AChE) activity, serum corticosterone (CORT), and increased brain-derived neurotrophic factor (BDNF) levels, respectively, compared to LUT suspension. Histopathological examination confirmed nearly preserved hippocampal architecture in PEGylated LUT-Aspasome-treated rats. These effects are attributed to LUT encapsulation within PEGylated Aspasomes, which enhanced stability, brain delivery, and neuroprotective efficacy. Thus, PEGylated LUT-Aspasomes are a promising strategy for managing stress-related neurobehavioral disorders.
- 6 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (4)
Open AccessPEGylated Flavonoid Aspasomes as a Brain-Targeted Nano-Vesicular Platform for Enhanced Neuroprotection in Stress-Induced Cognitive Dysfunction
Luteolin (LUT) is a biologically active flavonoid exhibiting significant therapeutic potential against neurodegenerative disorders such as cognitive impairment. Nonetheless, its clinical application is limited by poor aqueous solubility, extensive first-pass metabolism and diminished permeability across the blood-brain barrier (BBB) and consequently, low oral bioavailability. This study aimed to develop PEGylated LUT nano-vesicular delivery systems to enhance brain delivery and therapeutic efficacy. PEGylated LUT-Aspasomes were prepared via thin-film hydration, using Brij 52 for PEGylation. Sixteen formulations were designed using a 24 full factorial design, varying the weights of Ascorbyl Palmitate (AP), Cholesterol (CH), Brij 52, and Span (Sp) type. The optimized formulation (F14) is composed of 40 mg AP and CH, 10 mg Brij 52, and 50 mg Sp 60 with a desirability value (0.747). F14 demonstrated entrapment efficiency (EE%) (86.24 ± 1.16%), particle size (PS) (188.30 ± 1.50 nm), and zeta potential (ZP) (-25.31 ± 0.84 mV). TEM confirmed spherical, nanosized vesicles with uniform morphology. XRD analysis revealed transformation of LUT from crystalline to amorphous form, supporting successful encapsulation. Drug release and ex-vivo nasal permeation were enhanced 3.4- and fourfold, respectively, compared to free LUT. In-vivo studies in chronic unpredictable stress (CUS) rats revealed that the optimized PEGylated LUT-Aspasomes significantly enhanced neuroprotective effects compared to free LUT. Treated rats exhibited improved spatial memory and a 1.7-fold greater attenuation of depressive-like behavior relative to free LUT. Biochemically, F14 produced 1.15-, 1.23-, and 1.06-fold superior reductions in hippocampal acetylcholinesterase (AChE) activity, serum corticosterone (CORT), and increased brain-derived neurotrophic factor (BDNF) levels, respectively, compared to LUT suspension. Histopathological examination confirmed nearly preserved hippocampal architecture in PEGylated LUT-Aspasome-treated rats. These effects are attributed to LUT encapsulation within PEGylated Aspasomes, which enhanced stability, brain delivery, and neuroprotective efficacy. Thus, PEGylated LUT-Aspasomes are a promising strategy for managing stress-related neurobehavioral disorders.
- Open Access
- 31 March 2025
- Published by Springer Nature in BMC Microbiology
- Vol. 25 (1) , 1-18
Luteolin loaded PEGylated cerosomes: a novel treatment for MRSA skin infections
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of skin and soft tissue infections which, due to the spread of antimicrobial resistance, have become increasingly serious. Bacterial skin infection affects the barrier function of skin causing depletion of the ceramide content in the stratum corneum (SC) of the epidermis. In the study reported herein, luteolin (LUT) a naturally-occurring flavonoid was incorporated in PEGylated cerosomes (PCs) to boost its antibacterial action as a topical application. The opimal formulation of the surface-modified lipidic vesicles was chosen with the aid of a 23 full factorial design. The effectiveness of the optimal LUT formulation which was developed was evaluated using several MRSA strains both in vitro and in vivo studies. Results: A 23 full factorial design was employed for the preparation of the optimum PC formulation, designated herein as F5. A comparative in vitro release study revealed the superiority of F5 over a LUT suspension in solubilizing and releasing after 24 h, a higher percentage 78.1 ± 1.8% of luteolin compared with only 18.3 ± 2.1% for the luteolin suspension. When tested against MRSA strains, F5 showed antimicrobial activity that was higher than that of the luteolin suspension, having a MIC value of 187.5 µg/mL versus 1500 µg/mL. In addition to having enhanced anti-virulence activity than the luteolin suspension in terms of antibiofilm formation (with % inhibition ranging from 45 to 99% with the tested strains at 0.5 × and 0.25 × MICs, where the luteolin suspension only had a range from 1 to 45%), enhanced anti-pigment production, and anti-α-hemolysin activity were also observed. Moreover, F5 affected the cell wall integrity as confirmed by transmission electron microscopy (TEM). Scanning electron microscopy (SEM) verified the effect of F5 on bacterial biofilm formation, showing reduction of cellular adhesion and disruption of biofilm, factors which greatly contribute to bacterial pathogenesis and antibiotic resistance. When compared to the negative control and the luteolin suspension groups, the F5 formulation also resulted in reducing the bacterial load in the murine skin infection model. Conclusions: F5 PEGylated cerosomes are potential new potent defense agents against MRSA infections, demonstrating promising therapeutic capabilities.
- 31 March 2025
- Published by Springer Nature in BMC Microbiology
- Vol. 25 (1) , 1-18
Open AccessLuteolin loaded PEGylated cerosomes: a novel treatment for MRSA skin infections
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of skin and soft tissue infections which, due to the spread of antimicrobial resistance, have become increasingly serious. Bacterial skin infection affects the barrier function of skin causing depletion of the ceramide content in the stratum corneum (SC) of the epidermis. In the study reported herein, luteolin (LUT) a naturally-occurring flavonoid was incorporated in PEGylated cerosomes (PCs) to boost its antibacterial action as a topical application. The opimal formulation of the surface-modified lipidic vesicles was chosen with the aid of a 23 full factorial design. The effectiveness of the optimal LUT formulation which was developed was evaluated using several MRSA strains both in vitro and in vivo studies. Results: A 23 full factorial design was employed for the preparation of the optimum PC formulation, designated herein as F5. A comparative in vitro release study revealed the superiority of F5 over a LUT suspension in solubilizing and releasing after 24 h, a higher percentage 78.1 ± 1.8% of luteolin compared with only 18.3 ± 2.1% for the luteolin suspension. When tested against MRSA strains, F5 showed antimicrobial activity that was higher than that of the luteolin suspension, having a MIC value of 187.5 µg/mL versus 1500 µg/mL. In addition to having enhanced anti-virulence activity than the luteolin suspension in terms of antibiofilm formation (with % inhibition ranging from 45 to 99% with the tested strains at 0.5 × and 0.25 × MICs, where the luteolin suspension only had a range from 1 to 45%), enhanced anti-pigment production, and anti-α-hemolysin activity were also observed. Moreover, F5 affected the cell wall integrity as confirmed by transmission electron microscopy (TEM). Scanning electron microscopy (SEM) verified the effect of F5 on bacterial biofilm formation, showing reduction of cellular adhesion and disruption of biofilm, factors which greatly contribute to bacterial pathogenesis and antibiotic resistance. When compared to the negative control and the luteolin suspension groups, the F5 formulation also resulted in reducing the bacterial load in the murine skin infection model. Conclusions: F5 PEGylated cerosomes are potential new potent defense agents against MRSA infections, demonstrating promising therapeutic capabilities.
- 9 September 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 646, 123385
Investigating the superiority of chitosan/D-alpha-tocopheryl polyethylene glycol succinate binary coated bilosomes in promoting the cellular uptake and anti-SARS-CoV-2 activity of polyphenolic herbal drug candidate
- 9 September 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 646, 123385
Investigating the superiority of chitosan/D-alpha-tocopheryl polyethylene glycol succinate binary coated bilosomes in promoting the cellular uptake and anti-SARS-CoV-2 activity of polyphenolic herbal drug candidate
- 27 April 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 640, 122980
Experimental design of D-α-tocopherol polyethylene glycol 1000 succinate stabilized bile salt based Nano-vesicles for improved cytotoxicity and bioavailability of colchicine binding site inhibitor Candidates: In Vitro, in silico, and pharmacokinetic studies
- 27 April 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 640, 122980
Experimental design of D-α-tocopherol polyethylene glycol 1000 succinate stabilized bile salt based Nano-vesicles for improved cytotoxicity and bioavailability of colchicine binding site inhibitor Candidates: In Vitro, in silico, and pharmacokinetic studies
- Open Access
- 10 February 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 606
Chitosan Surface-Modified PLGA Nanoparticles Loaded with Cranberry Powder Extract as a Potential Oral Delivery Platform for Targeting Colon Cancer Cells
Nutraceutical cranberry powder extract (CBPE) has distinct polyphenols inhibiting colon cancer growth and proliferation. However, its oral therapeutic efficacy is hindered because of its low permeability. This study aims to formulate chitosan surface-modified PLGA nanoparticles (CS-PLGA NPs) for encapsulating CBPE and modulating its release rate, permeation, cell targeting, and, therefore, its cytotoxicity. A full 23 factorial design is employed to scrutinize the effect of lactide/glycolide ratio, PLGA weight, and stabilizer concentrations on entrapment efficiency percentage (EE%), particle size (PS), polydispersity index (PDI), and zeta potential (ZP). The optimum formula (F4) shows spherical particles with a relatively high EE% (72.30 ± 2.86%), an appropriate size of 370.10 ± 10.31 nm, PDI; 0.398 ± 0.001, and ZP; −5.40 ± 0.21 mV. Alongside the ATR-FTIR outcomes, the chitosan surface-modified formula (CS-F4) demonstrates a significant increase in particle size (417.67 ± 6.77 nm) and a shift from negative to positive zeta potential (+21.63 ± 2.46 mV), confirming the efficiency of surface modification with chitosan. The intestinal permeability of F4 and CS-F4 is significantly increased by 2.19- and 3.10-fold, respectively, compared to the CBPE solution, with the permeability coefficient (Papp) being 2.05 × 10−4 cm/min and 2.91 × 10−4 cm/min, for F4 and CS-F4, respectively, compared to the CBPE solution, 9.36 × 10−5 cm/min. Moreover, CS-F4 evidences significant caspase-3 protein level expression stimulation and significant inhibition of vascular endothelial growth factor (VEGF) and signal transducer and activator of transcription-3 (STAT-3) protein expression levels, confirming the superiority of CS-F4 for targeting HT-29 cells. Briefly, CS-PLGA NPs could be regarded as a prosperous delivery system of CBPE with enhanced permeation, cell targeting, and antitumor efficacy.
- 10 February 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 606
Open AccessChitosan Surface-Modified PLGA Nanoparticles Loaded with Cranberry Powder Extract as a Potential Oral Delivery Platform for Targeting Colon Cancer Cells
Nutraceutical cranberry powder extract (CBPE) has distinct polyphenols inhibiting colon cancer growth and proliferation. However, its oral therapeutic efficacy is hindered because of its low permeability. This study aims to formulate chitosan surface-modified PLGA nanoparticles (CS-PLGA NPs) for encapsulating CBPE and modulating its release rate, permeation, cell targeting, and, therefore, its cytotoxicity. A full 23 factorial design is employed to scrutinize the effect of lactide/glycolide ratio, PLGA weight, and stabilizer concentrations on entrapment efficiency percentage (EE%), particle size (PS), polydispersity index (PDI), and zeta potential (ZP). The optimum formula (F4) shows spherical particles with a relatively high EE% (72.30 ± 2.86%), an appropriate size of 370.10 ± 10.31 nm, PDI; 0.398 ± 0.001, and ZP; −5.40 ± 0.21 mV. Alongside the ATR-FTIR outcomes, the chitosan surface-modified formula (CS-F4) demonstrates a significant increase in particle size (417.67 ± 6.77 nm) and a shift from negative to positive zeta potential (+21.63 ± 2.46 mV), confirming the efficiency of surface modification with chitosan. The intestinal permeability of F4 and CS-F4 is significantly increased by 2.19- and 3.10-fold, respectively, compared to the CBPE solution, with the permeability coefficient (Papp) being 2.05 × 10−4 cm/min and 2.91 × 10−4 cm/min, for F4 and CS-F4, respectively, compared to the CBPE solution, 9.36 × 10−5 cm/min. Moreover, CS-F4 evidences significant caspase-3 protein level expression stimulation and significant inhibition of vascular endothelial growth factor (VEGF) and signal transducer and activator of transcription-3 (STAT-3) protein expression levels, confirming the superiority of CS-F4 for targeting HT-29 cells. Briefly, CS-PLGA NPs could be regarded as a prosperous delivery system of CBPE with enhanced permeation, cell targeting, and antitumor efficacy.